Biocon will hold a meeting of the Board of Directors of the Company on 16 May 2024.Powered by Capital Market - Live News

Biocon has issued corporate guarantee of USD 20 million on behalf of Biocon Generics Inc, wholly owned step down subsidiary of the Company. The corporate guarantee valid for 5 years is for securing a term loan facility of USD 20 million from Mizuho Bank. Powered by Capital Market - Live News

Biocon announced its inclusion in S&P`s Sustainability Yearbook 2024 for the second consecutive year, based on the S&P Global Corporate Sustainability Assessment (CSA) of Biocon and Biocon Biologics Limited for 2023. Sustainability is integral to Biocon`s business purpose, and the Group is executing a progressive Environment, Social and Governance (ESG) strategy aligned with stakeholder expectations and business objectives. Biocon`s S&P Global ESG score was 63 versus 52 previously, placing it among the Top 10 global biotechnology companies from within the 300 companies that were assessed. Powered by Capital Market - Live News

Biocon Biologics (subsidiary of Biocon) announced a five-year partnership with Sandoz AG (Sandoz) which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia. Under the agreement, Sandoz will distribute the Biocon Biologics` brands, OGIVRI� (bTrastuzumab) and ABEVMY� (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin� and Bevacizumab is a biosimilar of Avastin�3 � both biosimilars are available on the PBS and utilised for the treatment of various cancers. The agreement is effective from 01 January 2024 and commercialisation commenced on 01 February 2024.Powered by Capital Market - Live News

Biocon announced that the U.S. Food and Drug Administration (US FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for bBevacizumab. The CRL did not identify any outstanding scientific issues on the dossier and informs the need for the completion of a pre-approval inspection of the bBevacizumab manufacturing facility.Powered by Capital Market - Live News